This paper seeks to put the spotlight on the ongoing contestations in the area of trade negotiations, global intellectual property rights and access to medicines. It aims to shows that these contests are real and have important consequences on how global public health needs are met and on the form and shape of the emerging global IPRs regime. More specifically, it shows how the coalition of some developing countries and international health NGOs has scored some victories and lost ground elsewhere on the IPRs- access to medicines battle which is taking place both at the multilateral and bilateral level. It concludes that developing countries’ coalition needs to be both on the offensive and on the defensive, so as to defend past victories, cu...
The purpose of this article is to analyse how developments after the Doha Declaration went wrong; ho...
Over the past fifteen years, the United States and other developed countries have employed trade agr...
This impressive collection offers fascinating new perspectives on the impact of pharmaceutical paten...
After the Agreement on the Trade-Related Aspects of Intellectual Property Rights (TRIPS) came into o...
Developing countries have limited control over the distributional and substantive dimensions of inte...
Few issues are as controversial as the impact of intellectual property on health in developing count...
During the last years developed countries succeeded in introducing intellectual property rights into...
The price of medicines is one of the main barriers to treatment access for many poor people in devel...
This study explores how an 'Intellectual Property Rights (IPR)/trade regime' has generated a particu...
Over the past fifteen years, the United States and other developed countries have employed trade agr...
This article examines the many factors that have created and continue to perpetuate the ongo...
Paragraph 6 of the Doha Declaration on Public Health, dealing with access to medicines for countries...
The purpose of this article is to analyse how developments after the Doha Declaration went wrong; ho...
tion, provides for stringent patent protection in the name of intellectual property rights. This int...
Most discussions on the public health implications of the WTO Agreement on Trade-Related Aspects of ...
The purpose of this article is to analyse how developments after the Doha Declaration went wrong; ho...
Over the past fifteen years, the United States and other developed countries have employed trade agr...
This impressive collection offers fascinating new perspectives on the impact of pharmaceutical paten...
After the Agreement on the Trade-Related Aspects of Intellectual Property Rights (TRIPS) came into o...
Developing countries have limited control over the distributional and substantive dimensions of inte...
Few issues are as controversial as the impact of intellectual property on health in developing count...
During the last years developed countries succeeded in introducing intellectual property rights into...
The price of medicines is one of the main barriers to treatment access for many poor people in devel...
This study explores how an 'Intellectual Property Rights (IPR)/trade regime' has generated a particu...
Over the past fifteen years, the United States and other developed countries have employed trade agr...
This article examines the many factors that have created and continue to perpetuate the ongo...
Paragraph 6 of the Doha Declaration on Public Health, dealing with access to medicines for countries...
The purpose of this article is to analyse how developments after the Doha Declaration went wrong; ho...
tion, provides for stringent patent protection in the name of intellectual property rights. This int...
Most discussions on the public health implications of the WTO Agreement on Trade-Related Aspects of ...
The purpose of this article is to analyse how developments after the Doha Declaration went wrong; ho...
Over the past fifteen years, the United States and other developed countries have employed trade agr...
This impressive collection offers fascinating new perspectives on the impact of pharmaceutical paten...